As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to own the patient journey.
Feature|Podcasts|March 11, 2025
The Misinformation Maze: Navigating Public Health in the Digital Age
Author(s)Miranda Schmalfuhs
Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Advertisement
In this episode of the Pharmaceutical Executive podcast, Jennifer Butler, chief commercial officer of Pleio, discusses:
- The threat of misinformation to public health and how emotional appeal plays a part.
- Where patients are turning for trustworthy health information.
- Strategies that can be used to verify information.
- Pharma's role in helping to ensure patients have access to health insights they can trust.
- Why the industry is turning to peer-to-patient platforms, trusted patient communities, and pharmacies to educate patients.
- What kind of role regulatory agencies should play in the battle against misinformation.
- and more!
Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peet-to-patient strategies to educate patients, and more.
Advertisement
Related to this article
Six years after Rutledge, new court rulings, federal PBM reforms, and state ownership bans are redrawing the limits of pharmacy benefit regulation.
FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.
FDA has approved Welireg plus Lenvima for previously treated advanced clear cell renal cell carcinoma.
Numerof's Michael Abrams on why healthcare consolidation is the primary driver of rising employer costs — and why there's no end in sight.
InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.
FDA approves Onswik, Eli Lilly's once-weekly basal insulin for adults with type 2 diabetes.
EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business School names clinical data harmonization as the real barrier to enterprise AI adoption in life sciences, and Novo Nordisk's CEO says he's open to a direct NYSE listing.
Advertisement
Advertisement
Trending on PharmExec
1
InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly
2
From Experimentation to Execution: Strategic AI Adoption and Clinical Data Harmonization in Life Sciences
3
The Legacy of Rutledge: How States and Congress Can Still Regulate Pharmacy Benefit Managers
4
FDA Approves Onswik for Adults with Type 2 Diabetes
5